海辰药业(300584) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was ¥578,315,038.29, a decrease of 18.12% compared to ¥706,295,710.22 in 2020[19]. - Net profit attributable to shareholders was ¥285,878,182.25, an increase of 417.61% from ¥55,230,052.39 in 2020[19]. - The net profit after deducting non-recurring gains and losses was ¥24,051,742.89, down 54.66% from ¥53,042,549.07 in 2020[19]. - The total assets at the end of 2021 were ¥1,302,008,303.05, representing a 43.63% increase from ¥906,518,927.96 at the end of 2020[19]. - The weighted average return on equity was 35.18%, up 26.84 percentage points from 8.34% in 2020[19]. - The company reported a net cash flow from operating activities of ¥59,940,771.89, a decrease of 18.32% from ¥73,388,593.52 in 2020[19]. - The company received government subsidies amounting to ¥2,429,575.12 in 2021, down from ¥3,515,398.96 in 2020[24]. - The total sales amount from the top five customers was ¥67,337,192.84, accounting for 11.65% of the annual total sales[74]. - The total procurement amount from the top five suppliers was ¥16,200,667.32, representing 31.44% of the annual total procurement[75]. - The company reported a total procurement volume of 243,800 units for Rivaroxaban at a price of 72.31 RMB per 15mg*7 tablets in national procurement[52]. Dividend and Profit Distribution - The company reported a profit distribution plan based on a base of 120,000,000 shares, proposing a cash dividend of 2.50 RMB per 10 shares (including tax) and no bonus shares[5]. - The company distributed a cash dividend of RMB 1.25 per 10 shares, totaling RMB 15 million for the 2020 fiscal year[163]. - The company proposed a cash dividend of 2.50 CNY per 10 shares, totaling 30 million CNY for the year 2021, which represents 100% of the distributable profit[166]. - The company has no plans for stock bonuses or capital reserve transfers for the year 2021, with all undistributed profits carried forward to the next year[167]. - The independent directors have confirmed that the profit distribution plan aligns with the company's performance growth and protects the interests of all shareholders[166]. Research and Development - The company is focused on the development of generic drugs and aims to ensure quality and efficacy consistency with original drugs[13]. - The company is engaged in ongoing research and development to innovate new products and technologies in the pharmaceutical field[13]. - The company has established a strong presence in the pharmaceutical market, with a focus on expanding its product offerings and market reach[13]. - The company is actively enhancing its R&D capabilities, focusing on both independent and collaborative research to ensure a continuous pipeline of new products[46]. - The company has submitted three invention patent applications, strengthening its intellectual property protection and enhancing core competitiveness[51]. - The company is advancing multiple R&D projects, including the completion of the synthesis process for Dabigatran and the establishment of corresponding quality standards[78]. - The company has ongoing applications for various products, including Apixaban and Montelukast, which are currently under review, indicating a robust pipeline[49]. - The company plans to enhance research and development efficiency and focus on innovation management in 2022[110]. - The company has established a dedicated team for innovative drug research to foster new drug development[110]. Market and Product Development - The company has 73 approved drug products, with major products included in the 2021 National Medical Insurance Directory[36]. - The company’s main products include Torasemide injection, Tigecycline injection, and Labetalol hydrochloride injection, which are positioned in various therapeutic areas[36]. - The company’s Torasemide injection is a new generation diuretic with a strong and lasting effect, but faced market challenges due to low-priced competitors[36]. - The company has completed the registration for the seventh batch of national drug procurement for Tigecycline injection, aiming to enhance market coverage[37]. - The company is focusing on improving product quality standards through consistency evaluation applications for several injectable products, which are expected to enhance competitiveness[49]. - The company is actively expanding its market presence for injectable Labetalol and Rivaroxaban tablets, which are expected to be major growth points in 2022[113]. - The company aims to optimize its product structure with the inclusion of new products in the medical insurance directory, which is expected to drive growth[109]. Operational Efficiency and Cost Management - The company is committed to reducing drug procurement prices through volume-based procurement strategies, which could alleviate medical expenses[13]. - The company has established a complete quality management system and maintains stable relationships with key suppliers, ensuring smooth procurement channels[42]. - The company's operating costs decreased due to a decline in annual revenue, with fixed costs increasing as a percentage of total costs[73]. - The company reported a 60.03% decrease in raw material costs, which accounted for 35.09% of total operating costs in 2021[73]. - The company has established a marketing network covering over 1,000 distributors and approximately 3,000 hospitals nationwide[65]. - The company is expanding its online and offline sales channels to enhance its marketing strategy[65]. Governance and Compliance - The company has established a comprehensive governance structure, including a board of directors and supervisory board, ensuring effective checks and balances[129]. - The company maintains complete independence from its controlling shareholder in terms of assets, personnel, finance, and operations, ensuring a fully independent business model[130]. - The company has a structured governance framework with clear responsibilities among the shareholders' meeting, board of directors, and supervisory board[171]. - The company has a clear governance structure that includes independent oversight by non-executive directors[146]. - The company has a performance evaluation system to assess the effectiveness of its directors and senior management annually[147]. - The company has maintained compliance with regulatory requirements regarding the remuneration of its board members and executives[148]. Environmental Responsibility - The company has implemented a waste gas treatment process with a 90% efficiency rate for organized waste gas, ensuring compliance with emission standards[181]. - The company has constructed a 100 tons per day wastewater treatment facility, which further discharges to the local wastewater treatment plant for additional purification[183]. - The company has established a solid hazardous waste storage facility and follows strict regulations for the storage and transfer of hazardous waste[182]. - The company has conducted environmental monitoring for air and water quality throughout 2021, with all results meeting regulatory standards[185]. - The company actively participates in environmental protection and sustainable development, ensuring compliance with environmental regulations and investing in clean production facilities[188]. Employee and Training Initiatives - The total number of employees at the end of the reporting period was 563, with 186 in production, 105 in sales, and 155 in technical roles[160]. - The company conducted 231 training sessions during the reporting period, totaling 1,517 hours, to enhance employee skills and efficiency[162]. - The company has a competitive compensation policy that includes basic salary, sales bonuses, and various employee benefits[161]. - The company aims to enhance employee capabilities through various training programs, contributing to its competitive edge in the pharmaceutical industry[171]. Risks and Challenges - The company emphasizes the importance of understanding risks such as industry policy changes, drug price reduction risks, and R&D risks, which could impact future performance[5]. - The company is facing risks from industry policy changes, including price reductions due to centralized procurement, which may impact profitability[117][118]. - The company reported a significant impact from natural disasters and public health emergencies on its operations, which could affect normal production and business activities[123].